Project SIMPLIFY – A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg…

Basic data

Acronym:
SIMPLIFY
Title:
A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis
Duration:
01/01/2016 to 01/01/2016
Abstract / short description:
A Multicenter, Open-Label Immunogenicity and Safety Study of subcutaneous Natalizumab 300 mg administered to Subjects with Relapsing Multiple Sclerosis
Keywords:
multiple sclerosis
Multiple Sklerose

Staff

Managers

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Contact persons

Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Department of Diagnostic and Interventional Neuroradiology
Department of Radiology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Maidenhead, United Kingdom
Help

will be deleted permanently. This cannot be undone.